Brief: Clinuvel Pharmaceuticals Says FY Revenue From Ordinary Activities Up 19% To A$78.3 Mln
29/08/2023 02:32
Aug 29 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* FY REVENUE FROM ORDINARY ACTIVITIES UP 19% TO A$78.3
MILLION
* FY NET PROFIT ATTRIBUTABLE UP 47% TO A$30.6 MILLION
* FULLY FRANKED FINAL DIVIDEND OF A$0.05 PER SHARE DECLARED
* EXPANSION TRAJECTORY WILL CONTINUE INTO FY24
Source text for Eikon: ID:nASXcbZwBv
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist